BST2 Antikörper

Produktnummer ABIN2664561

Dieses Ratte Monoklonal-Antikörper erkennt spezifisch BST2 in FACS, IHC, IF, IP und BR. Er zeigt eine Reaktivität gegenüber Maus.

Kurzübersicht für BST2 Antikörper (ABIN2664561)

Target: BST2 (Bone Marrow Stromal Cell Antigen 2 (BST2))

Reaktivität: Maus

Wirt: Ratte

Klonalität: Monoklonal

Konjugat: Dieser BST2 Antikörper ist unkonjugiert

Applikation: Flow Cytometry (FACS), Immunohistochemistry (IHC), Immunofluorescence (IF), Immunoprecipitation (IP), Blocking Reagent (BR)

Klon: 129c1

Produktdetails anti-BST2 Antikörper

Aufreinigung: The antibody was purified by affinity chromatography.

Isotyp: IgG2b kappa

Anwendungsinformationen

Applikationshinweise: Optimal working dilution should be determined by the investigator.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Konzentration: 0.5 mg/mL

Buffer: Phosphate-buffered solution, pH 7.2, containing 0.09 % sodium azide.

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Lagerung: 4 °C

Informationen zur Lagerung: The antibody solution should be stored undiluted between 2°C and 8°C.

Details zu BST2

Target: BST2 (Bone Marrow Stromal Cell Antigen 2 (BST2))

Andere Bezeichnung: CD317

Hintergrund: CD317, known as BST2, tetherin, HM1.2 antigen, bone marrow stromal antigen 2, or PDCA-1, is type II transmembrane glycoprotein with a molecular mass of 29-33 kD. It is predominantly expressed on Type I IFN-producing cells (IPCs) in naive mice, but is up-regulated on most cell types following stimulation with type I IFNs and IFN-gamma. It is highly expressed on terminally differentiated normal plasmacytoid dendritic cells and some tumor cells, such as multiple myeloma, renal cell carcinoma, and melanoma cells. BST2 is a recently identified as IFN-induced cellular response factor that blocks release of HIV-1 and other retroviruses from infected cells. BST2 has been found to be the natural ligand of ILT7 in human model.

Pathways: Regulation of Leukocyte Mediated Immunity, Production of Molecular Mediator of Immune Response